Innovacell
Latest round
- Series D
Last raised
- Aug 2025
Total raised
- Undisclosed
Investors
- 7
About Innovacell
a. innovacell, specializes in regenerative medicine.3 billion in an IPO, selling 9,125,300 shares at JPY 1350 per share at the Growth Market.3 billion. The company specializes in the development and commercialization of regenerative medicine products utilizing human cells. The firm’s primary focus is on creating cell-based therapies aimed at addressing urinary and fecal incontinence, with three distinct autologous cell treatment pipelines currently under development. These therapies are designed to improve the quality of life for patients suffering from these conditions by enhancing their ability to manage incontinence. Innovacell’s products are developed through research and exploration of human cell applications across various global markets. Innovacell generates revenue through the commercialization of its regenerative medicine products, particularly focusing on partnerships with healthcare providers and institutions. The company structures its transactions through collaborations in the healthcare sector, involving business-to-business agreements with hospitals, clinics, and medical professionals who utilize their therapies.
Who invested in Innovacell
7 investors across 1 round
See all investors in Innovacell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Aug 21, 2025
Amount
Undisclosed
Investors
Questions about Innovacell
Who invested in Innovacell?
Innovacell has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innovacell raised?
Innovacell has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innovacell last raise money?
Innovacell's most recent round on record is a Series D, in Aug 2025.
What does Innovacell do?
Innovacell is a biotechnology company.
Where is Innovacell headquartered?
Innovacell is headquartered in Tokyo, Japan.
Which VCs invest in companies like Innovacell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Innovacell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Innovacell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.